Valuation: CROSSJECT

Market Cap 86.02M 100M 80.74M 73.74M 139M 9.56B 140M 955M 370M 4.82B 376M 368M 15.97B P/E 2026 *
3.85x
P/E 2027 * 3.04x
Enterprise Value 68.12M 79.37M 63.94M 58.4M 110M 7.57B 111M 757M 293M 3.82B 298M 292M 12.65B EV / Sales 2026 *
1.12x
EV / Sales 2027 * 0.92x
Free-Float
91.83%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 07/08/2001
Director of Finance/CFO - 24/03/2026
Corporate Officer/Principal - 19/08/2024
Director TitleAgeSince
Chairman 67 25/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+5.66%+19.59%-21.70%-32.63% 126M
+6.76%+9.42%+6.04%-60.50% 94.03M
-2.48%+2.15%+98.90%+54.10% 90.33M
+4.93%+13.31%+61.29%-11.83% 64.08M
Average +3.72%+10.44%+36.13%-12.72% 93.63M
Weighted average by Cap. +3.85%+10.76%+28.55%-15.15%

Financials

2026 *2027 *
Net sales 60.8M 70.84M 57.07M 52.12M 98.37M 6.76B 98.84M 675M 262M 3.41B 266M 260M 11.29B 42.3M 49.28M 39.7M 36.26M 68.44M 4.7B 68.77M 470M 182M 2.37B 185M 181M 7.85B
Net income 28.3M 32.97M 26.56M 24.26M 45.79M 3.14B 46.01M 314M 122M 1.59B 124M 121M 5.25B 7.75M 9.03M 7.27M 6.64M 12.54M 861M 12.6M 86.08M 33.36M 434M 33.9M 33.17M 1.44B
Net Debt -17.9M -20.86M -16.8M -15.34M -28.96M -1.99B -29.1M -199M -77.05M -1B -78.3M -76.61M -3.32B -47M -54.76M -44.11M -40.29M -76.04M -5.22B -76.41M -522M -202M -2.63B -206M -201M -8.73B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-